Roberto José Pessoa de Magalhães Filho
Instituição:
Universidade Federal do Rio de Janeiro
Centro:
Hospital Universitário Clementino Fraga/CCS
Unidade:
Hospital Universitário Clementino Fraga/CCS
Departamento:
Divisão Médica DMD/HU
Formação:
-
Universidade Federal do Rio de Janeiro
Clínica Médica | Doutorado | 2011 - 2015
-
Universidad de Salamanca
citometria de fluxo | Aperfeiçoamento | 2010 - 2012
-
Universidade Federal do Rio de Janeiro
Clínica Médica | Mestrado | 2007 - 2009
-
Universidade do Estado do Rio de Janeiro
| Especialização - Residência medica | 2000 - 2002
-
Universidade Federal do Estado do Rio de Janeiro
Nefrologia | Aperfeiçoamento | 1998 - 1999
-
Universidade Federal do Estado do Rio de Janeiro
Medicina | Graduação | 1993 - 1999
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:
(81.58% artigos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil | 10.3390/cancers15051605 | 2023 |
| COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality -cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM) | 10.1016/j.htct.2023.08.002 | 2023 |
| Comparison between computed tomography and magnetic resonance imaging in detecting multiple myeloma lesions in the skull: A systematic review | 10.1007/s40336-023-00605-0 | 2023 |
| CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil | 10.1016/j.htct.2022.08.002 | 2022 |
| Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2022. Part I | 10.1016/j.htct.2022.06.003 | 2022 |
| B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients | 10.3390/cancers13071704 | 2021 |
| HSCT for Monoclonal gammopathies: multiple myeloma and amyloidosis | 10.46765/2675-374X.2021 | 2021 |
| COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM) | 10.1182/blood-2021-153629 | 2021 |
| Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel - ABHH monoclonal gammopathies committe | 10.1016/j.htct.2020.05.001 | 2020 |
| Oral health status of patients with multiple myeloma | 10.1016/j.htct.2019.01.012 | 2020 |
| Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation | 10.1016/j.htct.2019.05.004 | 2019 |
| New proteasome inhibitors in the treatment of multiple myeloma | 10.1016/j.htct.2018.07.003 | 2019 |
| Bisphophonate alterations of the jaw bones in individuals with multiple myeloma | 10.1259/dmfr.20190155 | 2019 |
| Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy | 10.1182/blood.2019002610 | 2019 |
| Minimal residual disease and quality sample evaluation by Next Generation Flow cytometry in multiple myeloma patients: a Brazilian experience | 10.1016/j.clml.2019.09.299 | 2019 |
| Can dentists detect multiple myeloma through oral manifestations? | 10.1016/j.bjhh.2017.08.006 | 2018 |
| Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries | 10.1016/j.clml.2018.08.005 | 2018 |
| Impact of Treatment on B-Cell Regeneration By Next Generation Flow Cytometry in Patients with Multiple Myeloma | 10.1182/blood-2018-99-117162 | 2018 |
| Imaging of Jaw Lesions Related to Multiple Myeloma | 2017 | |
| Superiority of triple combination bortezomib + cyclophosphamide and dexamethasone (VCD) versus thalidomide + cyclophosphamide and dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant - Eligible Patients | 2017 | |
| Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible | 10.1007/s00277-015-2537-2 | 2016 |
| Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma | 10.1002/ajh.23274 | 2012 |
| Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry | 10.3324/haematol.2012.067272 | 2012 |
| 6q Deletion Helps in the Discrimination Between Symptomatic Waldenstro-m's Macroglobulinemia and Asymptomatic Forms of IgM Monoclonal Gammopathies | 10.1182/blood.V120.21.4566.4566 | 2012 |
| Differential Diagnosis of IgM MGUS and WM According to B-Lymphoid Infiltration by Morphology and Flow Cytometry | 10.3816/CLML.2011.n.017 | 2011 |
| Multidimensional Flow Cytometric (MFC) Analysis of the Immune System of Multiple Myeloma (MM) Patients Achieving Long Term Disease Control | 10.1182/blood.V118.21.810.810 | 2011 |
| Post-Treatment Bone Marrow Residual Disease > 5% by Flow Cytometry Is Highly Predictive of Short Progression-Free and Overall Survival in Patients With Waldenström's Macroglobulinemia | 10.3816/CLML.2011.n.040 | 2011 |
| Methylation status of nine tumor suppressor genes in multiple myeloma | 10.1007/s12185-009-0459-2 | 2010 |
| Fluorescence In Situ Hybridization (FISH) Analysis In 160 Patients with IgM Monoclonal Gammopathies | 10.1182/blood.V116.21.1916.1916 | 2010 |
| Risk assessment for multiple myeloma: preliminary results of the brazilian myeloma study group | 10.1590/S1516-84842008000800004 | 2008 |
| Transplante de células tronco hematopoéticas no mieloma múltiplo | 2007 | |
| Mieloma múltiplo e insuficiência renal | 2007 | |
| O transplante autólogo de células-tronco hematopoéticas no tratamento do Mieloma Múltiplo | 10.1590/S1516-84842007000100009 | 2007 |
| Mieloma Múltiplo e insuficiência renal | 10.1590/S1516-84842007000100016 | 2007 |
| Hypermethylation of DAP-K Is an Adverse Prognostic Factor in Patients with Multiple Myeloma (MM). | 10.1182/blood.V108.11.2220.2220 | 2006 |
| ínico atípico em leucemia mielóide crônica (LMC) com duplo cromossomo Philadelphia (Ph) expressando como único transcrito BCR-ABL a isoforma e1a2 | 2004 | |
| Apresentação atípica de DECH após utilização do protocolo Flag-IDA como resgate de recaída LMA M7 após transplante alogênico de medula óssea - Relato de caso | 2004 | |
| Derivado (!:20) (q10; q10): uma nova translocação desbalanceada em síndrome | 2004 |
Eventos:
(0.00% eventos com DOI)